{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Renovaro, Inc.
Is Renovaro, Inc. technically bullish or bearish?
As of June 9, 2025, Renovaro, Inc. shows a mildly bearish trend, with mixed signals from moving averages and Bollinger Bands, despite mildly bullish MACD readings.
Who are in the management team of Renovaro, Inc.?
As of March 2022, the management team of Renovaro, Inc. includes Mr. Rene Sindlev (Independent Chairman), Dr. Mark Dybul (Executive Vice Chairman and Principal Executive Officer), Mr. Henrik Gronfeldt-Sorensen, Mr. Gregg Alton, Dr. Carol Brosgart, and Ms. Evelyn D'An (all Independent Directors). They oversee the company's strategic direction and operations.
What does Renovaro, Inc. do?
Renovaro, Inc. is a biotechnology company focused on developing vaccines for colorectal cancer and gene therapies for HIV/AIDS, classified as a micro-cap with a market cap of $61.88 million. It currently reports no net sales or profits and has a debt equity ratio of 0.06.
How big is Renovaro, Inc.?
As of Jun 18, Renovaro, Inc. has a market capitalization of 61.88 million and reported net sales of 0.00 million with a net profit of -74.78 million for the latest four quarters. As of Jun 24, shareholder's funds are at 131.98 million and total assets at 163.13 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
